Clinical trials: Hepatic Neoplasm
Liver Cancer
Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00079027
- Testing
- doxorubicin hydrochloride, hepatic artery embolization
- Where
- 10 sites in United Kingdom
- Volunteers
- 280 people
- Sponsor
- University Hospital Birmingham
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Carcinoma, Hepatocellular
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable hepatocellular carcinoma…
- Trial name
- NeoLeap-HCC (NCT05389527)
- Testing
- Pembrolizumab+Lenvatinib
- Where
- 4 sites in China
- Volunteers
- 43 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Carcinoma, Liver Transplant; Complications
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
This study will evaluate the safety and efficacy of durvalumab in combination with lenvatinib in participants with locally advanced hepatocellular carcinoma before liver transplant and metastatic unresectable HCC.The primary…
- Trial name
- Dulect2020-1 (NCT04443322)
- Testing
- Durvalumab Injection, Lenvatinib 4 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Liver Cancer
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
- Trial name
- IRE (NCT02333773)
- Testing
- Irreversible electroporation (IRE)
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00987766
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
- Trial name
- NCT04541173
- Testing
- Y-90 TARE, Atezolizumab, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aiwu Ruth He, MD
Graft Rejection, Hepatocellular Carcinoma
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC. The combination of the ICI and other treatment regimens (Anti-VEGF, locoregional therapies et al) produced superior results in patients with…
- Conditions
- Graft Rejection, Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT05913583
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoplasms
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment
- Trial name
- NCT02696642
- Testing
- Anetumab ravtansine (BAY94-9343)
- Where
- 8 sites in France, Moldova
- Volunteers
- 54 people
- Sponsor
- Bayer
Liver Cancer
CIRSE Registry for SIR-Spheres in France (CIRT-FR)
Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, is a minimal invasive, endovascular treatment for primary and secondary liver tumours.
- Trial name
- CIRT-FR (NCT03256994)
- Testing
- Yttrium-90 loaded SIR-Spheres microspheres, QLQ-C30 with HCC module
- Where
- 13 sites in France
- Volunteers
- 332 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Pancreatic Cancer, Liver Cancer
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
The preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by the Cancer Vision Googles (CVG) with LS301 in animal models.
- Conditions
- Pancreatic Cancer, Liver Cancer, Gastric Cancer, Gastrointestinal Stromal Cancer
- Trial name
- NCT04105062
- Testing
- LS301, Cancer Vision Goggles
- Sponsor
- Washington University School of Medicine
Hepatocellular Carcinoma
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection.
- Trial name
- NCT03812562
- Testing
- Nivolumab, Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.
- Trial name
- NCT05093608
- Testing
- Selinexor Pill, Bevacizumab, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus < = 2) and calculation method (bidimensional versus unidimensional).
- Trial name
- NCT04553458
- Testing
- Radiofrequency ablation, Trance-arterial chemoembolization, Liver resection
- Volunteers
- 407 people
- Sponsor
- Sohag University
Hepatocellular Carcinoma
Expanding Phase III Study of Tyroserleutide for Injection
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT03516448
- Testing
- Gan Fu Le Tablets, Tyroserleutide for injection
- Volunteers
- 352 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
HCC, Hepatocellular Carcinoma
Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study
Non-invasive MRI subclassification of Heptocellular Carcinoma - HepCaSt-Study
- Conditions
- HCC, Hepatocellular Carcinoma, MRI
- Trial name
- HepCaSt (NCT05202015)
- Testing
- MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Liver Cancer
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).
- Trial name
- ICGMFITinPLC (NCT05160740)
- Testing
- Indocyanine green for injection
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Zhujiang Hospital
Pancreatic Cancer
Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs
The study aims to compare the use of a microsieve device vs a cell surface marker-based platform for the isolation of pancreatic cancer circulating tumor cells
- Trial name
- NCT04638868
- Testing
- Microsieve device, Cell surface marker-based platform
- Volunteers
- 26 people
- Sponsor
- Singapore General Hospital
Carcinoma, Hepatocellular
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine recommended Phase 2 dose [RP2D]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF)…
- Trial name
- NCT02421185
- Testing
- JNJ-42756493 (erdafitinib)
- Where
- 10 sites in China, South Korea and 1 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.